Global Self-administered Parenteral Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Self-administered Parenteral: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Self-administered Parenteral Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Pre-filled Syringes
1.2.3 Autoinjectors
1.2.4 Pen Injectors
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Self-administered Parenteral Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmacy
1.3.3 Online Sales
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Self-administered Parenteral Revenue Estimates and Forecasts 2020-2031
2.2 Global Self-administered Parenteral Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Self-administered Parenteral Sales Estimates and Forecasts 2020-2031
2.4 Global Self-administered Parenteral Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Self-administered Parenteral Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Self-administered Parenteral Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Pre-filled Syringes Market Size by Manufacturers
3.5.2 Autoinjectors Market Size by Manufacturers
3.5.3 Pen Injectors Market Size by Manufacturers
3.5.4 Others Market Size by Manufacturers
3.6 Global Self-administered Parenteral Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Self-administered Parenteral Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Self-administered Parenteral Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Self-administered Parenteral Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Self-administered Parenteral Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Self-administered Parenteral Sales and Revenue by Type (2020-2031)
6.4 North America Self-administered Parenteral Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Self-administered Parenteral Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Self-administered Parenteral Sales and Revenue by Type (2020-2031)
7.4 Europe Self-administered Parenteral Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Self-administered Parenteral Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Self-administered Parenteral Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Self-administered Parenteral Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Self-administered Parenteral Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Self-administered Parenteral Sales and Revenue by Type (2020-2031)
9.4 Central and South America Self-administered Parenteral Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Self-administered Parenteral Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Self-administered Parenteral Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Self-administered Parenteral Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Self-administered Parenteral Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Becton, Dickinson and Company
11.1.1 Becton, Dickinson and Company Corporation Information
11.1.2 Becton, Dickinson and Company Business Overview
11.1.3 Becton, Dickinson and Company Self-administered Parenteral Product Models, Descriptions and Specifications
11.1.4 Becton, Dickinson and Company Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Becton, Dickinson and Company Self-administered Parenteral Sales by Product in 2024
11.1.6 Becton, Dickinson and Company Self-administered Parenteral Sales by Application in 2024
11.1.7 Becton, Dickinson and Company Self-administered Parenteral Sales by Geographic Area in 2024
11.1.8 Becton, Dickinson and Company Self-administered Parenteral SWOT Analysis
11.1.9 Becton, Dickinson and Company Recent Developments
11.2 scPharmaceuticals
11.2.1 scPharmaceuticals Corporation Information
11.2.2 scPharmaceuticals Business Overview
11.2.3 scPharmaceuticals Self-administered Parenteral Product Models, Descriptions and Specifications
11.2.4 scPharmaceuticals Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 scPharmaceuticals Self-administered Parenteral Sales by Product in 2024
11.2.6 scPharmaceuticals Self-administered Parenteral Sales by Application in 2024
11.2.7 scPharmaceuticals Self-administered Parenteral Sales by Geographic Area in 2024
11.2.8 scPharmaceuticals Self-administered Parenteral SWOT Analysis
11.2.9 scPharmaceuticals Recent Developments
11.3 Harro Hofliger
11.3.1 Harro Hofliger Corporation Information
11.3.2 Harro Hofliger Business Overview
11.3.3 Harro Hofliger Self-administered Parenteral Product Models, Descriptions and Specifications
11.3.4 Harro Hofliger Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Harro Hofliger Self-administered Parenteral Sales by Product in 2024
11.3.6 Harro Hofliger Self-administered Parenteral Sales by Application in 2024
11.3.7 Harro Hofliger Self-administered Parenteral Sales by Geographic Area in 2024
11.3.8 Harro Hofliger Self-administered Parenteral SWOT Analysis
11.3.9 Harro Hofliger Recent Developments
11.4 Owen Mumford
11.4.1 Owen Mumford Corporation Information
11.4.2 Owen Mumford Business Overview
11.4.3 Owen Mumford Self-administered Parenteral Product Models, Descriptions and Specifications
11.4.4 Owen Mumford Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Owen Mumford Self-administered Parenteral Sales by Product in 2024
11.4.6 Owen Mumford Self-administered Parenteral Sales by Application in 2024
11.4.7 Owen Mumford Self-administered Parenteral Sales by Geographic Area in 2024
11.4.8 Owen Mumford Self-administered Parenteral SWOT Analysis
11.4.9 Owen Mumford Recent Developments
11.5 Haselmeier
11.5.1 Haselmeier Corporation Information
11.5.2 Haselmeier Business Overview
11.5.3 Haselmeier Self-administered Parenteral Product Models, Descriptions and Specifications
11.5.4 Haselmeier Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Haselmeier Self-administered Parenteral Sales by Product in 2024
11.5.6 Haselmeier Self-administered Parenteral Sales by Application in 2024
11.5.7 Haselmeier Self-administered Parenteral Sales by Geographic Area in 2024
11.5.8 Haselmeier Self-administered Parenteral SWOT Analysis
11.5.9 Haselmeier Recent Developments
11.6 Stevanato Group
11.6.1 Stevanato Group Corporation Information
11.6.2 Stevanato Group Business Overview
11.6.3 Stevanato Group Self-administered Parenteral Product Models, Descriptions and Specifications
11.6.4 Stevanato Group Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Stevanato Group Recent Developments
11.7 Ypsomed AG
11.7.1 Ypsomed AG Corporation Information
11.7.2 Ypsomed AG Business Overview
11.7.3 Ypsomed AG Self-administered Parenteral Product Models, Descriptions and Specifications
11.7.4 Ypsomed AG Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Ypsomed AG Recent Developments
11.8 Solteam Group
11.8.1 Solteam Group Corporation Information
11.8.2 Solteam Group Business Overview
11.8.3 Solteam Group Self-administered Parenteral Product Models, Descriptions and Specifications
11.8.4 Solteam Group Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Solteam Group Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Corporation Information
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Self-administered Parenteral Product Models, Descriptions and Specifications
11.9.4 AstraZeneca Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 AstraZeneca Recent Developments
11.10 Enable lnjections
11.10.1 Enable lnjections Corporation Information
11.10.2 Enable lnjections Business Overview
11.10.3 Enable lnjections Self-administered Parenteral Product Models, Descriptions and Specifications
11.10.4 Enable lnjections Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Enable lnjections Recent Developments
11.11 CCBio
11.11.1 CCBio Corporation Information
11.11.2 CCBio Business Overview
11.11.3 CCBio Self-administered Parenteral Product Models, Descriptions and Specifications
11.11.4 CCBio Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 CCBio Recent Developments
11.12 Phillips-Medisize Corporation
11.12.1 Phillips-Medisize Corporation Corporation Information
11.12.2 Phillips-Medisize Corporation Business Overview
11.12.3 Phillips-Medisize Corporation Self-administered Parenteral Product Models, Descriptions and Specifications
11.12.4 Phillips-Medisize Corporation Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Phillips-Medisize Corporation Recent Developments
11.13 Sorrel Medical
11.13.1 Sorrel Medical Corporation Information
11.13.2 Sorrel Medical Business Overview
11.13.3 Sorrel Medical Self-administered Parenteral Product Models, Descriptions and Specifications
11.13.4 Sorrel Medical Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Sorrel Medical Recent Developments
11.14 Krontec Healthcare
11.14.1 Krontec Healthcare Corporation Information
11.14.2 Krontec Healthcare Business Overview
11.14.3 Krontec Healthcare Self-administered Parenteral Product Models, Descriptions and Specifications
11.14.4 Krontec Healthcare Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Krontec Healthcare Recent Developments
11.15 Subcuject Aps
11.15.1 Subcuject Aps Corporation Information
11.15.2 Subcuject Aps Business Overview
11.15.3 Subcuject Aps Self-administered Parenteral Product Models, Descriptions and Specifications
11.15.4 Subcuject Aps Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Subcuject Aps Recent Developments
11.16 Ascendia Pharmaceuticals
11.16.1 Ascendia Pharmaceuticals Corporation Information
11.16.2 Ascendia Pharmaceuticals Business Overview
11.16.3 Ascendia Pharmaceuticals Self-administered Parenteral Product Models, Descriptions and Specifications
11.16.4 Ascendia Pharmaceuticals Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Ascendia Pharmaceuticals Recent Developments
11.17 West Pharmaceutical Services, Inc.
11.17.1 West Pharmaceutical Services, Inc. Corporation Information
11.17.2 West Pharmaceutical Services, Inc. Business Overview
11.17.3 West Pharmaceutical Services, Inc. Self-administered Parenteral Product Models, Descriptions and Specifications
11.17.4 West Pharmaceutical Services, Inc. Self-administered Parenteral Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 West Pharmaceutical Services, Inc. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Self-administered Parenteral Industry Chain
12.2 Self-administered Parenteral Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Self-administered Parenteral Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Self-administered Parenteral Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Self-administered Parenteral Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Self-administered Parenteral Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Self-administered Parenteral Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Self-administered Parenteral Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Self-administered Parenteral Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Self-administered Parenteral Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Self-administered Parenteral Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Self-administered Parenteral Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Self-administered Parenteral Sales by Region (2020-2025) & (K Units)
Table 8. Global Self-administered Parenteral Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Self-administered Parenteral Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Self-administered Parenteral Sales Share by Manufacturers (2020-2025)
Table 12. Global Self-administered Parenteral Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Self-administered Parenteral Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Self-administered Parenteral by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Self-administered Parenteral as of 2024)
Table 16. Global Self-administered Parenteral Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Self-administered Parenteral Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Self-administered Parenteral Manufacturing Base and Headquarters
Table 19. Global Self-administered Parenteral Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Self-administered Parenteral Sales by Type (2020-2025) & (K Units)
Table 23. Global Self-administered Parenteral Sales by Type (2026-2031) & (K Units)
Table 24. Global Self-administered Parenteral Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Self-administered Parenteral Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Self-administered Parenteral ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Self-administered Parenteral Sales by Application (2020-2025) & (K Units)
Table 29. Global Self-administered Parenteral Sales by Application (2026-2031) & (K Units)
Table 30. Self-administered Parenteral High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Self-administered Parenteral Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Self-administered Parenteral Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Self-administered Parenteral ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Self-administered Parenteral Growth Accelerators and Market Barriers
Table 37. North America Self-administered Parenteral Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Self-administered Parenteral Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Self-administered Parenteral Growth Accelerators and Market Barriers
Table 40. Europe Self-administered Parenteral Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Self-administered Parenteral Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Self-administered Parenteral Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Self-administered Parenteral Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Self-administered Parenteral Growth Accelerators and Market Barriers
Table 45. Southeast Asia Self-administered Parenteral Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Self-administered Parenteral Investment Opportunities and Key Challenges
Table 47. Central and South America Self-administered Parenteral Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Self-administered Parenteral Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Self-administered Parenteral Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Becton, Dickinson and Company Corporation Information
Table 51. Becton, Dickinson and Company Description and Major Businesses
Table 52. Becton, Dickinson and Company Product Models, Descriptions and Specifications
Table 53. Becton, Dickinson and Company Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Becton, Dickinson and Company Sales Value Proportion by Product in 2024
Table 55. Becton, Dickinson and Company Sales Value Proportion by Application in 2024
Table 56. Becton, Dickinson and Company Sales Value Proportion by Geographic Area in 2024
Table 57. Becton, Dickinson and Company Self-administered Parenteral SWOT Analysis
Table 58. Becton, Dickinson and Company Recent Developments
Table 59. scPharmaceuticals Corporation Information
Table 60. scPharmaceuticals Description and Major Businesses
Table 61. scPharmaceuticals Product Models, Descriptions and Specifications
Table 62. scPharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. scPharmaceuticals Sales Value Proportion by Product in 2024
Table 64. scPharmaceuticals Sales Value Proportion by Application in 2024
Table 65. scPharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. scPharmaceuticals Self-administered Parenteral SWOT Analysis
Table 67. scPharmaceuticals Recent Developments
Table 68. Harro Hofliger Corporation Information
Table 69. Harro Hofliger Description and Major Businesses
Table 70. Harro Hofliger Product Models, Descriptions and Specifications
Table 71. Harro Hofliger Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Harro Hofliger Sales Value Proportion by Product in 2024
Table 73. Harro Hofliger Sales Value Proportion by Application in 2024
Table 74. Harro Hofliger Sales Value Proportion by Geographic Area in 2024
Table 75. Harro Hofliger Self-administered Parenteral SWOT Analysis
Table 76. Harro Hofliger Recent Developments
Table 77. Owen Mumford Corporation Information
Table 78. Owen Mumford Description and Major Businesses
Table 79. Owen Mumford Product Models, Descriptions and Specifications
Table 80. Owen Mumford Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Owen Mumford Sales Value Proportion by Product in 2024
Table 82. Owen Mumford Sales Value Proportion by Application in 2024
Table 83. Owen Mumford Sales Value Proportion by Geographic Area in 2024
Table 84. Owen Mumford Self-administered Parenteral SWOT Analysis
Table 85. Owen Mumford Recent Developments
Table 86. Haselmeier Corporation Information
Table 87. Haselmeier Description and Major Businesses
Table 88. Haselmeier Product Models, Descriptions and Specifications
Table 89. Haselmeier Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Haselmeier Sales Value Proportion by Product in 2024
Table 91. Haselmeier Sales Value Proportion by Application in 2024
Table 92. Haselmeier Sales Value Proportion by Geographic Area in 2024
Table 93. Haselmeier Self-administered Parenteral SWOT Analysis
Table 94. Haselmeier Recent Developments
Table 95. Stevanato Group Corporation Information
Table 96. Stevanato Group Description and Major Businesses
Table 97. Stevanato Group Product Models, Descriptions and Specifications
Table 98. Stevanato Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Stevanato Group Recent Developments
Table 100. Ypsomed AG Corporation Information
Table 101. Ypsomed AG Description and Major Businesses
Table 102. Ypsomed AG Product Models, Descriptions and Specifications
Table 103. Ypsomed AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Ypsomed AG Recent Developments
Table 105. Solteam Group Corporation Information
Table 106. Solteam Group Description and Major Businesses
Table 107. Solteam Group Product Models, Descriptions and Specifications
Table 108. Solteam Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Solteam Group Recent Developments
Table 110. AstraZeneca Corporation Information
Table 111. AstraZeneca Description and Major Businesses
Table 112. AstraZeneca Product Models, Descriptions and Specifications
Table 113. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. AstraZeneca Recent Developments
Table 115. Enable lnjections Corporation Information
Table 116. Enable lnjections Description and Major Businesses
Table 117. Enable lnjections Product Models, Descriptions and Specifications
Table 118. Enable lnjections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Enable lnjections Recent Developments
Table 120. CCBio Corporation Information
Table 121. CCBio Description and Major Businesses
Table 122. CCBio Product Models, Descriptions and Specifications
Table 123. CCBio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. CCBio Recent Developments
Table 125. Phillips-Medisize Corporation Corporation Information
Table 126. Phillips-Medisize Corporation Description and Major Businesses
Table 127. Phillips-Medisize Corporation Product Models, Descriptions and Specifications
Table 128. Phillips-Medisize Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Phillips-Medisize Corporation Recent Developments
Table 130. Sorrel Medical Corporation Information
Table 131. Sorrel Medical Description and Major Businesses
Table 132. Sorrel Medical Product Models, Descriptions and Specifications
Table 133. Sorrel Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Sorrel Medical Recent Developments
Table 135. Krontec Healthcare Corporation Information
Table 136. Krontec Healthcare Description and Major Businesses
Table 137. Krontec Healthcare Product Models, Descriptions and Specifications
Table 138. Krontec Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Krontec Healthcare Recent Developments
Table 140. Subcuject Aps Corporation Information
Table 141. Subcuject Aps Description and Major Businesses
Table 142. Subcuject Aps Product Models, Descriptions and Specifications
Table 143. Subcuject Aps Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Subcuject Aps Recent Developments
Table 145. Ascendia Pharmaceuticals Corporation Information
Table 146. Ascendia Pharmaceuticals Description and Major Businesses
Table 147. Ascendia Pharmaceuticals Product Models, Descriptions and Specifications
Table 148. Ascendia Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Ascendia Pharmaceuticals Recent Developments
Table 150. West Pharmaceutical Services, Inc. Corporation Information
Table 151. West Pharmaceutical Services, Inc. Description and Major Businesses
Table 152. West Pharmaceutical Services, Inc. Product Models, Descriptions and Specifications
Table 153. West Pharmaceutical Services, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. West Pharmaceutical Services, Inc. Recent Developments
Table 155. Key Raw Materials Distribution
Table 156. Raw Materials Key Suppliers
Table 157. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 158. Milestones in Production Technology Evolution
Table 159. Distributors List
Table 160. Market Trends and Market Evolution
Table 161. Market Drivers and Opportunities
Table 162. Market Challenges, Risks, and Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources


List of Figures
Figure 1. Self-administered Parenteral Product Picture
Figure 2. Global Self-administered Parenteral Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Pre-filled Syringes Product Picture
Figure 4. Autoinjectors Product Picture
Figure 5. Pen Injectors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Self-administered Parenteral Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Pharmacy
Figure 9. Online Sales
Figure 10. Other
Figure 11. Self-administered Parenteral Report Years Considered
Figure 12. Global Self-administered Parenteral Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 14. Global Self-administered Parenteral Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Self-administered Parenteral Revenue Market Share by Region (2020-2031)
Figure 16. Global Self-administered Parenteral Sales (2020-2031) & (K Units)
Figure 17. Global Self-administered Parenteral Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Self-administered Parenteral Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Self-administered Parenteral Sales Volume Market Share in 2024
Figure 20. Global Self-administered Parenteral Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Pre-filled Syringes Revenue Market Share by Manufacturer in 2024
Figure 23. Autoinjectors Revenue Market Share by Manufacturer in 2024
Figure 24. Pen Injectors Revenue Market Share by Manufacturer in 2024
Figure 25. Others Revenue Market Share by Manufacturer in 2024
Figure 26. Global Self-administered Parenteral Sales Market Share by Type (2020-2031)
Figure 27. Global Self-administered Parenteral Revenue Market Share by Type (2020-2031)
Figure 28. Global Self-administered Parenteral Sales Market Share by Application (2020-2031)
Figure 29. Global Self-administered Parenteral Revenue Market Share by Application (2020-2031)
Figure 30. North America Self-administered Parenteral Sales YoY (2020-2031) & (K Units)
Figure 31. North America Self-administered Parenteral Revenue YoY (2020-2031) & (US$ Million)
Figure 32. North America Top 5 Manufacturers Self-administered Parenteral Sales Revenue (US$ Million) in 2024
Figure 33. North America Self-administered Parenteral Sales Volume (K Units) by Type (2020- 2031)
Figure 34. North America Self-administered Parenteral Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 35. North America Self-administered Parenteral Sales Volume (K Units) by Application (2020-2031)
Figure 36. North America Self-administered Parenteral Sales Revenue (US$ Million) by Application (2020-2031)
Figure 37. US Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 38. Canada Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 39. Mexico Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 40. Europe Self-administered Parenteral Sales YoY (2020-2031) & (K Units)
Figure 41. Europe Self-administered Parenteral Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Europe Top 5 Manufacturers Self-administered Parenteral Sales Revenue (US$ Million) in 2024
Figure 43. Europe Self-administered Parenteral Sales Volume (K Units) by Type (2020-2031)
Figure 44. Europe Self-administered Parenteral Sales Revenue (US$ Million) by Type (2020-2031)
Figure 45. Europe Self-administered Parenteral Sales Volume (K Units) by Application (2020-2031)
Figure 46. Europe Self-administered Parenteral Sales Revenue (US$ Million) by Application (2020-2031)
Figure 47. Germany Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 48. France Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 49. U.K. Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 50. Italy Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 51. Russia Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Self-administered Parenteral Sales YoY (2020-2031) & (K Units)
Figure 53. Asia-Pacific Self-administered Parenteral Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Asia-Pacific Top 8 Manufacturers Self-administered Parenteral Sales Revenue (US$ Million) in 2024
Figure 55. Asia-Pacific Self-administered Parenteral Sales Volume (K Units) by Type (2020- 2031)
Figure 56. Asia-Pacific Self-administered Parenteral Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 57. Asia-Pacific Self-administered Parenteral Sales Volume (K Units) by Application (2020-2031)
Figure 58. Asia-Pacific Self-administered Parenteral Sales Revenue (US$ Million) by Application (2020-2031)
Figure 59. Indonesia Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 60. Japan Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 61. South Korea Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 62. China Taiwan Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 63. India Self-administered Parenteral Revenue (2020-2031) & (US$ Million)
Figure 64. Central and South America Self-administered Parenteral Sales YoY (2020-2031) & (K Units)
Figure 65. Central and South America Self-administered Parenteral Revenue YoY (2020-2031) & (US$ Million)
Figure 66. Central and South America Top 5 Manufacturers Self-administered Parenteral Sales Revenue (US$ Million) in 2024
Figure 67. Central and South America Self-administered Parenteral Sales Volume (K Units) by Type (2021-2031)
Figure 68. Central and South America Self-administered Parenteral Sales Revenue (US$ Million) by Type (2020-2031)
Figure 69. Central and South America Self-administered Parenteral Sales Volume (K Units) by Application (2020-2031)
Figure 70. Central and South America Self-administered Parenteral Sales Revenue (US$ Million) by Application (2020-2031)
Figure 71. Brazil Self-administered Parenteral Revenue (2020-2025) & (US$ Million)
Figure 72. Argentina Self-administered Parenteral Revenue (2020-2025) & (US$ Million)
Figure 73. Middle East, and Africa Self-administered Parenteral Sales YoY (2020-2031) & (K Units)
Figure 74. Middle East and Africa Self-administered Parenteral Revenue YoY (2020-2031) & (US$ Million)
Figure 75. Middle East and Africa Top 5 Manufacturers Self-administered Parenteral Sales Revenue (US$ Million) in 2024
Figure 76. Middle East and Africa Self-administered Parenteral Sales Volume (K Units) by Type (2021-2031)
Figure 77. South America Self-administered Parenteral Sales Revenue (US$ Million) by Type (2020-2031)
Figure 78. Middle East and Africa Self-administered Parenteral Sales Volume (K Units) by Application (2020-2031)
Figure 79. Middle East and Africa Self-administered Parenteral Sales Revenue (US$ Million) by Application (2020-2031)
Figure 80. GCC Countries Self-administered Parenteral Revenue (2020-2025) & (US$ Million)
Figure 81. Turkey Self-administered Parenteral Revenue (2020-2025) & (US$ Million)
Figure 82. Egypt Self-administered Parenteral Revenue (2020-2025) & (US$ Million)
Figure 83. South Africa Self-administered Parenteral Revenue (2020-2025) & (US$ Million)
Figure 84. Self-administered Parenteral Industry Chain Mapping
Figure 85. Regional Self-administered Parenteral Manufacturing Base Distribution (%)
Figure 86. Global Self-administered Parenteral Production Market Share by Region (2020-2031)
Figure 87. Self-administered Parenteral Production Process
Figure 88. Regional Self-administered Parenteral Production Cost Structure
Figure 89. Channels of Distribution (Direct Vs Distribution)
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit